Literature DB >> 6684684

Maintenance of behavior by postponement of scheduled injections of nicotine in squirrel monkeys.

R D Spealman.   

Abstract

Responding by squirrel monkeys was maintained under a schedule of i.v. nicotine postponement. Each lever-pressing response postponed an impending i.v. injection for 60 sec; in the absence of responding, injections occurred very 20 sec. The lowest dose of nicotine (10 micrograms/kg/injection) maintained rates of responding that were only slightly higher than those maintained by saline. Intermediate doses (30 or 56 micrograms/kg/injection), however, maintained rates and patterns of responding that were similar to those maintained by electric shock under an identical schedule of postponement. At the highest dose (100 micrograms/kg/injection), nicotine disrupted responding and induced vomiting in each monkey. Presession treatment with mecamylamine (1.0 mg/kg i.m.), a nicotinic antagonist with both central and peripheral effects, shifted the nicotine dose-response curve to the right by about 1 log unit and blocked nicotine-induced emesis. In contrast, presession treatment with hexamethonium (1.0 or 10.0 mg/kg i.m.), a nicotinic antagonist with primarily peripheral effects, did not produce an overall rightward shift in the nicotine dose-response curve, although it did reduce the rate of responding maintained by the intermediate doses of nicotine and blocked emesis. Neither mecamylamine nor hexamethonium systematically altered responding maintained by electric shock under the schedule of postponement. The results show that schedule-characteristic performances can be maintained by postponement of i.v. injections of nicotine and that the maintenance of responding under the postponement schedule depends largely on the actions of nicotine in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684684

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Individual differences in the reinforcing and punishing effects of nicotine in rhesus monkeys.

Authors:  Mikhail N Koffarnus; Gail Winger
Journal:  Psychopharmacology (Berl)       Date:  2015-02-08       Impact factor: 4.530

2.  Nicotine as a typical drug of abuse in experimental animals and humans.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-10-05       Impact factor: 4.530

3.  Response-dependent versus response-independent presentation of cocaine: differences in the lethal effects of the drug.

Authors:  S I Dworkin; S Mirkis; J E Smith
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

4.  Nicotine induces conditioned place preferences over a large range of doses in rats.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

Review 5.  Addiction as a BAD, a Behavioral Allocation Disorder.

Authors:  R J Lamb; Brett C Ginsburg
Journal:  Pharmacol Biochem Behav       Date:  2017-05-02       Impact factor: 3.533

6.  Nicotinic aspects of the discriminative stimulus effects of arecoline.

Authors:  Gail Winger
Journal:  Behav Pharmacol       Date:  2021-10-01       Impact factor: 2.277

Review 7.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Self-administration of cocaine and nicotine mixtures by rhesus monkeys.

Authors:  Kevin B Freeman; William L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  2009-08-13       Impact factor: 4.530

Review 9.  Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases.

Authors:  Paul L R Andrews; Charles C Horn
Journal:  Auton Neurosci       Date:  2006-03-23       Impact factor: 3.145

10.  Reinforcing effectiveness of nicotine in nonhuman primates: effects of nicotine dose and history of nicotine self-administration.

Authors:  Stephen J Kohut; Jack Bergman
Journal:  Psychopharmacology (Berl)       Date:  2016-04-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.